![]() ![]() “Once complete, this data set will provide a wealth of new information about the human genome and accelerate the study of disease in - and discovery of new therapeutics for - populations less well represented in prior large-scale sequencing efforts. ![]() “The initial cohort will be among the largest sequencing efforts involving African Americans to date,” said Leeland Ekstrom, chief executive officer of Nashville Biosciences. “The whole-genome sequencing of these 35,000 samples will work toward greater diversity of genomic data to ultimately enable improved access to precision therapies for all people,” said Joydeep Goswami, chief strategy and corporate development officer and interim chief financial officer of Illumina. ![]() The patients who provided them consented to research use, and the samples are linked to extensive de-identified clinical data derived from VUMC’s electronic medical records. The BioVU samples were extracted from blood collected during routine clinical testing. Launched in 2022, the AGD aims to whole-genome sequence at least 250,000 de-identified human DNA samples from VUMC’s BioVU biobank over two and a half years in collaboration with multiple biopharmaceutical companies. Sequencing this set of samples is the first in Illumina and Nashville Biosciences’ Alliance for Genomic Discovery (AGD), a multiyear agreement to accelerate therapeutic development through large-scale genomics and establish a preeminent clinico-genomic data set. This lack of diversity in genomic data has created a gap in the scientific understanding of the underlying genetic causes of disease and inhibits equitable access to precision health therapies. It’s widely recognized that most genomic data sets are drawn from people of European ancestry. This cohort will be the largest data set of genomes of its kind to date. The sample cohort is primarily made up of DNA from African Americans, who are currently underrepresented in research for the clinical applications of genomics, including drug target discovery. Nashville Biosciences LLC, a wholly owned subsidiary of Vanderbilt University Medical Center, and Illumina Inc., a global leader in DNA sequencing and array-based technologies, today announced an agreement with Amgen, a global biopharmaceutical company, to whole-genome sequence approximately 35,000 DNA samples. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |